Functional validation of a novel STAT3 'variant of unknown significance' identifies a new case of STAT3 GOF Syndrome and reveals broad immune cell defects.

IF 3.4 3区 医学 Q3 IMMUNOLOGY
Joseph Mackie, Daniel Suan, Peter McNaughton, Filomeen Haerynck, Michael O'Sullivan, Antoine Guerin, Cindy S Ma, Stuart G Tangye
{"title":"Functional validation of a novel STAT3 'variant of unknown significance' identifies a new case of STAT3 GOF Syndrome and reveals broad immune cell defects.","authors":"Joseph Mackie, Daniel Suan, Peter McNaughton, Filomeen Haerynck, Michael O'Sullivan, Antoine Guerin, Cindy S Ma, Stuart G Tangye","doi":"10.1093/cei/uxaf005","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>STAT3 orchestrates crucial immune responses through its pleiotropic functions as a transcription factor. Patients with germline monoallelic dominant negative or hypermorphic STAT3 variants, who present with immunodeficiency and/or immune dysregulation, have revealed the importance of balanced STAT3 signaling in lymphocyte differentiation and function, and immune homeostasis. Here, we report a novel missense variant of unknown significance in the DNA binding domain of STAT3 in a patient who experienced hypogammaglobulinemia, lymphadenopathy, hepatosplenomegaly, immune thrombocytopenia, eczema and enteropathy over a 35-year period.</p><p><strong>Methods: </strong>In vitro demonstration of prolonged STAT3 activation due to delayed de-phosphorylation, and enhanced transcriptional activity, confirmed this to be a novel pathogenic STAT3 gain-of-function variant. Peripheral blood lymphocytes from this patient, and patients with confirmed STAT3 Gain-of-function Syndrome, were collected to investigate mechanisms of disease pathogenesis.</p><p><strong>Results: </strong>B cell dysregulation was evidenced by a loss of class-switched memory B cells and a significantly expanded CD19hiCD21lo B cell population, likely influenced by a skewed CXCR3+ TFH population. Interestingly, unlike STAT3 dominant negative variants, cytokine secretion by activated peripheral blood STAT3 GOF CD4+ T cells and frequencies of Treg cells were intact, suggesting CD4+ T cell dysregulation likely occurs at sites of disease rather than the periphery.</p><p><strong>Conclusion: </strong>This study provides an in-depth case study in confirming a STAT3 gain-of-function variant and identifies lymphocyte dysregulation in peripheral blood of patients with STAT3 Gain-of-function Syndrome. Identifying cellular biomarkers of disease provide a flow cytometric based screen to guide validation of additional novel STAT3 gain-of-function variants as well as provide insights into putative mechanisms of disease pathogenesis.</p>","PeriodicalId":10268,"journal":{"name":"Clinical and experimental immunology","volume":" ","pages":""},"PeriodicalIF":3.4000,"publicationDate":"2025-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and experimental immunology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/cei/uxaf005","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: STAT3 orchestrates crucial immune responses through its pleiotropic functions as a transcription factor. Patients with germline monoallelic dominant negative or hypermorphic STAT3 variants, who present with immunodeficiency and/or immune dysregulation, have revealed the importance of balanced STAT3 signaling in lymphocyte differentiation and function, and immune homeostasis. Here, we report a novel missense variant of unknown significance in the DNA binding domain of STAT3 in a patient who experienced hypogammaglobulinemia, lymphadenopathy, hepatosplenomegaly, immune thrombocytopenia, eczema and enteropathy over a 35-year period.

Methods: In vitro demonstration of prolonged STAT3 activation due to delayed de-phosphorylation, and enhanced transcriptional activity, confirmed this to be a novel pathogenic STAT3 gain-of-function variant. Peripheral blood lymphocytes from this patient, and patients with confirmed STAT3 Gain-of-function Syndrome, were collected to investigate mechanisms of disease pathogenesis.

Results: B cell dysregulation was evidenced by a loss of class-switched memory B cells and a significantly expanded CD19hiCD21lo B cell population, likely influenced by a skewed CXCR3+ TFH population. Interestingly, unlike STAT3 dominant negative variants, cytokine secretion by activated peripheral blood STAT3 GOF CD4+ T cells and frequencies of Treg cells were intact, suggesting CD4+ T cell dysregulation likely occurs at sites of disease rather than the periphery.

Conclusion: This study provides an in-depth case study in confirming a STAT3 gain-of-function variant and identifies lymphocyte dysregulation in peripheral blood of patients with STAT3 Gain-of-function Syndrome. Identifying cellular biomarkers of disease provide a flow cytometric based screen to guide validation of additional novel STAT3 gain-of-function variants as well as provide insights into putative mechanisms of disease pathogenesis.

一种新的STAT3“未知意义变异”的功能验证鉴定了STAT3 GOF综合征的新病例,并揭示了广泛的免疫细胞缺陷。
简介:STAT3通过其作为转录因子的多效性功能来协调关键的免疫反应。存在免疫缺陷和/或免疫失调的种系单等位基因显性阴性或高形态STAT3变异体患者,已经揭示了平衡STAT3信号在淋巴细胞分化和功能以及免疫稳态中的重要性。在这里,我们报告了一种新的意义不明的STAT3 DNA结合域的错义变异,该变异发生在一位经历过35年低γ球蛋白血症、淋巴结病、肝脾肿大、免疫性血小板减少症、湿疹和肠病的患者身上。方法:体外实验证明STAT3因延迟去磷酸化而延长激活时间,并增强转录活性,证实这是一种新的致病性STAT3功能获得变体。收集该患者及确诊STAT3功能获得综合征患者外周血淋巴细胞,探讨其发病机制。结果:B细胞失调的证据是类别转换记忆B细胞的缺失和CD19hiCD21lo B细胞群的显著扩增,这可能受到CXCR3+ TFH群体扭曲的影响。有趣的是,与STAT3显性阴性变异不同,活化的外周血STAT3 GOF CD4+ T细胞分泌的细胞因子和Treg细胞的频率是完整的,这表明CD4+ T细胞失调可能发生在疾病部位,而不是外周。结论:本研究提供了一个深入的案例研究,以确认STAT3功能获得变异,并识别STAT3功能获得综合征患者外周血淋巴细胞失调。识别疾病的细胞生物标志物提供了一种基于流式细胞术的筛选,以指导额外的新型STAT3功能获得变异的验证,并为假定的疾病发病机制提供见解。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
8.40
自引率
2.20%
发文量
101
审稿时长
3-8 weeks
期刊介绍: Clinical & Experimental Immunology (established in 1966) is an authoritative international journal publishing high-quality research studies in translational and clinical immunology that have the potential to transform our understanding of the immunopathology of human disease and/or change clinical practice. The journal is focused on translational and clinical immunology and is among the foremost journals in this field, attracting high-quality papers from across the world. Translation is viewed as a process of applying ideas, insights and discoveries generated through scientific studies to the treatment, prevention or diagnosis of human disease. Clinical immunology has evolved as a field to encompass the application of state-of-the-art technologies such as next-generation sequencing, metagenomics and high-dimensional phenotyping to understand mechanisms that govern the outcomes of clinical trials.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信